Bagsværd, Denmark, 29 July 2024 – On 6 May 2024, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules"). This programme is part of the overall share repurchase programme of up to DKK 20 billion to be executed during a 12-month period beginning 6 February 2024. Under the programme initiated 6 May 202 ...

Ozempic could pile up a lot more indications in the years ahead.Novo Nordisk (NVO -0.88%) has become one of the most valuable healthcare stocks in the world due in large part to Ozempic, its diabetes drug that has also been effective in helping people lose weight. One challenge for investors and analysts, however, is predicting just how much revenue it could bring in at its peak. As new studies emerge involving the drug, there are new possible benefits uncovered relating to the use of Ozempic.Recently, ther ...

The company should maintain its lead in this growing area.Novo Nordisk (NVO -0.88%) is under attack. Although the Denmark-based drugmaker is a pioneer and leader in the GLP-1 diabetes and weight loss drug markets, countless companies are trying to steal its lunch. It's no wonder: Ozempic, a diabetes medicine, and Wegovy, a weight loss therapy with the same active ingredient, have both seen incredible success. Challengers were bound to rise, eventually. However, Novo Nordisk is also working on potential succ ...

Novo Nordisk (NVO) is slated to report second-quarter 2024 results on Aug 7, before the opening bell. The Zacks Consensus Estimate for quarterly revenues in the to-be-reported quarter is pegged at $9.91 billion, while the same for earnings is pinned at 76 cents per share.In the past 30 days, the estimates for Novo Nordisk’s 2024 earnings per share (EPS) deteriorated from $3.41 to $3.38. During the same time frame, the forecast for the company’s 2025 EPS has improved from $4.30 to $4.35.Image Source: Zacks I ...

Boxes of Ozempic and Wegovy made by Novo Nordisk are seen at a pharmacy.Novo Nordisk's blockbuster Wegovy weight loss drug has received backing from the European Union's medical regulator to expand the medicine's use to include reducing the rise of serious heart events in overweight and obese adults.The Danish pharmaceutical giant on Thursday said that the European Medical Agency had adopted a "positive opinion" on the label expansion after reviewing the outcomes of a closely watched SELECT trial, opening t ...

LONDON — The U.K.'s health regulator on Tuesday approved the use of Novo Nordisk's Wegovy weight loss drug to reduce the risk of overweight and obese adults suffering from serious heart problems or strokes.The new approval from the U.K.'s Medicines and Healthcare products Regulatory Agency (MHRA) makes the Danish pharmaceutical giant's GLP-1 obesity drug the first in the country to be prescribed for prevention of cardiovascular events in people with obesity.It follows similar label expansion by the U.S. Foo ...

Loading...Loading...The famed Danish drug maker Novo Nordisk A/S NVO expressed disappointment on Wednesday following a recommendation by the Dutch Health Care Institute advising the Netherlands government against including the company’s popular weight-loss drug, Wegovy, in the basic insurance coverage.The institute’s recommendation, delivered on Tuesday, cited insufficient clarity on whether Wegovy’s health benefits justify its costs.Related: Bernie Sanders Targets High Prices of Ozempic and Wegovy In US.Al ...

In the latest market close, Novo Nordisk (NVO) reached $140.87, with a -0.37% movement compared to the previous day. This change lagged the S&P 500's daily gain of 0.64%. Elsewhere, the Dow saw an upswing of 1.85%, while the tech-heavy Nasdaq appreciated by 0.2%.The drugmaker's stock has climbed by 0.73% in the past month, exceeding the Medical sector's gain of 0.71% and lagging the S&P 500's gain of 3.82%.Analysts and investors alike will be keeping a close eye on the performance of Novo Nordisk in its upc ...

About this content About Ian Lyall Ian Lyall, a seasoned journalist and editor, brings over three decades of experience to his role as Managing Editor at Proactive. Overseeing Proactive's editorial and broadcast operations across six offices on three continents, Ian is responsible for quality control, editorial policy, and content production. He directs the creation of 50,000 pieces of real-time news, feature articles, and filmed interviews annually. Prior to Proactive, Ian helped lead the business outpu ...

Novo Nordisk (NVO) was once again in the news on Jul 12 after the University of Oxford announced results from an exploratory one-year study of semaglutide, a GLP-1 receptor agonist, showing that the drug was not associated with a risk of adverse neuropsychiatric outcomes compared with other antidiabetic medications. On the contrary, treatment with semaglutide was associated with benefits like lowering the risk of cognitive problems and nicotine misuse. This opens the scope for further evaluation of the drug ...